Risk of incident atrial fibrillation* in patients with gout compared with those with osteoarthritis
| Adjustment | HR (95% CI) |
|---|---|
| Main analysis | |
| Age, sex | 1.23 (1.14 to 1.32) |
| +Comorbidity score and number of prescription drugs | 1.19 (1.11 to 1.28) |
| Final model† | 1.13 (1.04 to 1.23) |
| Stratified analysis‡ | |
| By obesity | |
| Yes | 1.26 (1.02 to 1.56) |
| No | 1.18 (1.09 to 1.27) |
| By diabetes | |
| Yes | 1.11 (0.96 to 1.27) |
| No | 1.21 (1.11 to 1.31) |
| By history of CVD | |
| Yes | 1.25 (1.01 to 1.41) |
| No | 1.15 (1.05 to 1.26) |
| Subgroup analysis | |
| Patients with baseline ESR/CRP levels available (n=15 174) | |
| Age, sex | 1.17 (0.78 to 1.76) |
| +Comorbidity score and number of prescription drugs | 1.12 (0.74 to 1.69) |
| +High ESR/CRP | 1.06 (0.70 to 1.61) |
| Patients with baseline uric acid levels available (n=20 622) | |
| Age, sex | 1.32 (0.88 to 1.97) |
| +Comorbidity score and number of prescription drugs | 1.33 (0.89 to 2.00) |
| +Serum uric acid level | 1.19 (0.78 to 1.83) |
*Defined with an inpatient or outpatient diagnosis of AF and a dispensing of anticoagulants/antiarrhythmics.
†The final model includes age, sex, comorbidities, medications and healthcare usage factors listed in table 1.
‡Stratified analyses were adjusted for age, sex, comorbidity score and number of prescription drugs.
AF, atrial fibrillation; CRP, C reactive protein; CVD, cardiovascular disease; ESR, erythrocyte sedimentation rate.